H.C. Wainwright Reiterates a Buy Rating on Recro Pharma

By Ryan Adsit

In a report released today, Ed Arce from H.C. Wainwright reiterated a Buy rating on Recro Pharma (NASDAQ: REPH). The company’s shares closed last Friday at $8.04.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 16.3% and a 34.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics, Inc., and Sucampo Pharmaceuticals.

Currently, the analyst consensus on Recro Pharma is Strong Buy and the average price target is $21, representing a 161.2% upside.

In a report issued on November 10, Roth Capital also reiterated a Buy rating on the stock with a $24 price target.

The company has a one year high of $12.50 and a one year low of $5.59. Currently, Recro Pharma has an average volume of 60.77K.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of REPH in relation to earlier this year.

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company, whcih focused on products for hospitals and ambulatory care settings. The company is developing non-opioid products for treatment of serious acute pain. It offers drug solutions for cancer, musculoskeletal disorders and peripheral neuropathy, cancer breakthrough and acute post-operative pain. The company’s products include Dex-INR and Fadolmidine, which is under development. Recro Pharma was founded by Geraldine A. Henwood on November 15, 2007 and is headquartered in Malvern, PA.